Nomogram Shows Effect of Pleural Effusion on Myeloma Outcome
A team of investigators report on their validated nomogram that incorporates pleural effusion into the classification of disease severity in patients with multiple myeloma.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Prophylactic IVIG Is More Effective in Subgroups of Myeloma
A retrospective, single-center crossover study was conducted that compared rates of infection in patients with multiple myeloma during observation compared with those receiving IVIG.
Daratumumab Not Cost-Effective for Multiple Myeloma
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
Cost-Effectiveness Varies for Non-Transplant-Eligible Multiple Myeloma Treatment Sequences
Researchers compared clinical effectiveness and cost effectiveness of treatment regimens for multiple myeloma.
Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
IMiD-Free Regimen Effective in Relapsed/Refractory Multiple Myeloma
A single-arm, phase 2 trial was conducted to assess response to treatment with carfilzomib plus cyclophosphamide and dexamethasone among patients with relapsed/refractory multiple myeloma.
Paroxysmal Nocturnal Hemoglobinuria Clones Positive Predictor in Myelodysplastic Syndromes, Aplastic Anemia
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
Sarclisa Plus Carfilzomib and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
Patients With Multiple Myeloma Express Social and Financial Difficulties, High Symptom Burden
Semistructured interviews of patients and clinicians were conducted to explore how this disease affects the day-to-day lives of patients.
Abecma Approved for Relapsed/Refractory Multiple Myeloma
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression-free, three-year overall survival similar for lenalidomide maintenance regimen without dexamethasone.
Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
Can Premedications, Infusion Rates Be Adjusted Safely With Daratumumab for Multiple Myeloma?
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
Quantitative IgA Offers Superior Disease Monitoring in IgA Multiple Myeloma
For patients with IgA multiple myeloma, monitoring disease progression with quantitative IgA may be superior to the conventional approach.
MagnetisMM-3 Trial to Test BCMA-CD3 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
The phase 2 MagnetisMM-3 trial will test the safety and efficacy of subcutaneous elranatamab (PF-06863135) for relapsed or refractory multiple myeloma.
Study Confirms Efficacy, Safety of Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Researchers sought to confirm the efficacy and safety of 3 target doses of this B-cell maturation antigen-directed CAR-T therapy.
Descartes-11 Trial Tests RNA-Engineer Cell Therapy in Multiple Myeloma
Cartesian Therapeutics launches a trial of Descartes-11, which is designed to express CAR-T molecules transiently.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
